SCHEMBL4695643

SCHEMBL4695643

CCc1nc(NCC(O)(CC(C)(C)c2cccc3c2OCC3)C(F)(F)F)c2cnn(-c3ccc(F)cc3F)c2n1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 19/20 0.43
PGR P06401 10/20 0.43
NR3C2 P08235 8/20 0.43
AR P10275 1/20 0.37
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4694709 0.92 NR3C1 (0.44) NR3C1PGRNR3C2ARMEN1
SCHEMBL4696064 0.92 NR3C1 (0.44) NR3C1PGRNR3C2AR
SCHEMBL4697274 0.90 NR3C1 (0.44) NR3C1PGRNR3C2ARMEN1
SCHEMBL4697792 0.87 MEN1 (0.49) NR3C1PGRNR3C2ARMEN1
SCHEMBL4695856 0.86 NR3C1 (0.48) NR3C1PGRNR3C2ARMEN1
SCHEMBL304108 0.86 NR3C1 (0.47) NR3C1PGRNR3C2
SCHEMBL4695634 0.85 NR3C1 (0.42) NR3C1PGRNR3C2ARMEN1
SCHEMBL4697677 0.85 NR3C1 (0.47) NR3C1PGRNR3C2ARMEN1
SCHEMBL4694685 0.84 NR3C1 (0.42) NR3C1PGRNR3C2ARMEN1
SCHEMBL4696723 0.84 NR3C1 (0.43) NR3C1PGRNR3C2ARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080292561-A1 Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents GLAXO GROUP LIMITED 2008-11-27 US claimed
EP-1945642-A1 PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS GLAXO GROUP LIMITED (GB) 2008-07-23 EP claimed
WO-2007054294-A1 PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS GLAXO GROUP LIMITED (GB) 2007-05-18 WO claimed
US-20080292561-A1 Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents GLAXO GROUP LIMITED 2008-11-27 US disclosed
US-20080292561-A1 Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents GLAXO GROUP LIMITED 2008-11-27 US disclosed
US-20080292561-A1 Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents GLAXO GROUP LIMITED 2008-11-27 US disclosed
EP-1945642-A1 PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
WO-2007054294-A1 PYRAZOLO-PYRIMIDINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS GLAXO GROUP LIMITED (GB) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080292561-A1 Pyrazolo-Pyrimidine Derivatives as Anti-Inflammatory Agents NOD1, FPR3, FPR1 NR3C1 141/4885PGR 905/4885NR3C2 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.